Top

Published in:

01-02-2014 | Literatur kommentiert

Zusatz von Cetuximab zur primären Radiochemotherapie von Ösophaguskarzinomen verursacht schlechteres Gesamtüberleben

Authors: Dr. Dr. N.H. Nicolay, Prof. Dr. K. Herfarth

Published in: Strahlentherapie und Onkologie | Issue 2/2014

Auszug

Crosby T, Hurt CN, Falk S et al (2013) Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 14:627–637 …

Baumann M, Krause M (2004) Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72:257–266PubMedCrossRef

Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578PubMedCrossRef

Safran H, Suntharalingam M, Dipetrillo T et al (2008) Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 70:391–395PubMedCrossRef

Ruhstaller T, Pless M, Dietrich D et al (2011) Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 29:626–631PubMedCrossRef

Hurt CN, Nixon LS, Griffiths GO et al (2011) SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer 11:466PubMedCentralPubMedCrossRef

Wang KL, Wu TT, Choi IS et al (2007) Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109:658–667PubMedCrossRef

Chen Y, Wu X, Bu S et al (2012) Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma. Cancer Sci 103:1979–1984PubMedCrossRef

Okines AF, Gonzalez de Castro D, Cunningham D et al (2013) Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. Eur J Cancer. doi: 10.1016/j.ejca.2013.02.007. [Epub ahead of print]

10.

Okines AF, Ashley SE, Cunningham D et al (2010) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol 28:3945–3950PubMedCrossRef

Title: Zusatz von Cetuximab zur primären Radiochemotherapie von Ösophaguskarzinomen verursacht schlechteres Gesamtüberleben
Authors: Dr. Dr. N.H. Nicolay
Prof. Dr. K. Herfarth
Publication date: 01-02-2014
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 2/2014
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0523-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Zusatz von Cetuximab zur primären Radiochemotherapie von Ösophaguskarzinomen verursacht schlechteres Gesamtüberleben

Auszug

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 2/2014

Whole abdominopelvic radiotherapy in the palliative treatment of pseudomyxoma peritonei

External-beam radiation therapy after surgical resection and intraoperative electron-beam radiation therapy for oligorecurrent gynecological cancer

Dose-dependent deterioration of swallowing function after induction chemotherapy and definitive chemoradiotherapy for laryngopharyngeal cancer

Berechnungen der „equivalent uniform dose“ zur akzelerierten Teilbrustbestrahlung mit dem MammoSite-Applikator

Semiautomated volumetric response evaluation as an imaging biomarker in superior sulcus tumors

The QUIRO Study (assurance of quality and innovation in radiooncology): methodology, instruments and practices